MA51132A - Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci - Google Patents

Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci

Info

Publication number
MA51132A
MA51132A MA051132A MA51132A MA51132A MA 51132 A MA51132 A MA 51132A MA 051132 A MA051132 A MA 051132A MA 51132 A MA51132 A MA 51132A MA 51132 A MA51132 A MA 51132A
Authority
MA
Morocco
Prior art keywords
methylpiperidin
pyrazin
trifluoroethyl
dichloro
phenyl
Prior art date
Application number
MA051132A
Other languages
English (en)
Inventor
Rubio Silvina Garcia
Claudio Giuliano
Angelo Guainazzi
Mauro Perseghini
Claudio Pietra
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of MA51132A publication Critical patent/MA51132A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA051132A 2017-12-11 2018-12-07 Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci MA51132A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762597236P 2017-12-11 2017-12-11

Publications (1)

Publication Number Publication Date
MA51132A true MA51132A (fr) 2020-10-21

Family

ID=64901108

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051132A MA51132A (fr) 2017-12-11 2018-12-07 Sel de fumarate de l'urée (r)-3-(1-(2,3-dichloro-4-(pyrazin-2-yl)phényl)-2,2,2-trifluoroéthyl)-1-méthyl-1-(1-méthylpipéridin-4-yl), procédés de préparation et utilisations de celui-ci

Country Status (19)

Country Link
US (2) US11299472B2 (fr)
EP (1) EP3724176B1 (fr)
JP (1) JP7171728B2 (fr)
KR (1) KR20200097762A (fr)
CN (1) CN111683934B (fr)
AU (1) AU2018385438B2 (fr)
BR (1) BR112020010803A2 (fr)
CL (1) CL2020001553A1 (fr)
DK (1) DK3724176T3 (fr)
EA (1) EA202091402A1 (fr)
ES (1) ES2910030T3 (fr)
HU (1) HUE058247T2 (fr)
IL (1) IL275153B2 (fr)
LT (1) LT3724176T (fr)
MA (1) MA51132A (fr)
MX (1) MX2020006026A (fr)
SI (1) SI3724176T1 (fr)
WO (1) WO2019118298A1 (fr)
ZA (1) ZA202002957B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202400439T1 (it) 2017-12-11 2024-11-15 Univ Muenchen Tech Ligandi di psma per la formazione di immagini e endoradioterapia
CN111303192A (zh) * 2020-03-26 2020-06-19 西安瑞联新材料股份有限公司 一种3-氯-2-萘硼酸的工业化生产方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005048916A2 (fr) 2003-11-20 2005-06-02 Biovitrum Ab Nouvelles carbolines-beta en tant qu'antagonistes de recepteur de secretagogue d'hormone de croissance
WO2011060397A1 (fr) 2009-11-16 2011-05-19 Schering Corporation Amino heterocycles substitues utilises comme antagonistes du vih
WO2012113103A1 (fr) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Urées asymétriques et leurs utilisations médicales
TWI703130B (zh) 2014-03-07 2020-09-01 瑞士商赫爾辛保健股份有限公司 對位取代的不對稱脲及其醫療用途

Also Published As

Publication number Publication date
EP3724176A1 (fr) 2020-10-21
EP3724176B1 (fr) 2022-01-26
US11884646B2 (en) 2024-01-30
US20220340541A1 (en) 2022-10-27
CN111683934A (zh) 2020-09-18
ZA202002957B (en) 2025-04-30
CN111683934B (zh) 2024-01-23
MX2020006026A (es) 2020-08-17
AU2018385438A8 (en) 2020-06-04
IL275153A (en) 2020-07-30
US11299472B2 (en) 2022-04-12
WO2019118298A1 (fr) 2019-06-20
AU2018385438B2 (en) 2022-12-15
LT3724176T (lt) 2022-04-25
CL2020001553A1 (es) 2020-11-06
AU2018385438A1 (en) 2020-05-28
HUE058247T2 (hu) 2022-07-28
JP7171728B2 (ja) 2022-11-15
BR112020010803A2 (pt) 2020-11-10
IL275153B1 (en) 2024-08-01
US20200299260A1 (en) 2020-09-24
IL275153B2 (en) 2024-12-01
JP2021505633A (ja) 2021-02-18
CA3083509A1 (fr) 2019-06-20
DK3724176T3 (da) 2022-04-04
KR20200097762A (ko) 2020-08-19
ES2910030T3 (es) 2022-05-11
EA202091402A1 (ru) 2020-09-01
SI3724176T1 (sl) 2022-04-29

Similar Documents

Publication Publication Date Title
MA52781A (fr) Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MX2022004992A (es) Uso de compuestos de 3-isoxazolidinonas como herbicidas selectivos.
EP3787665A4 (fr) Systèmes, procédés et appareils d'électroporation
EP3484367A4 (fr) Prévention de l'encrassement biologique de capteurs portatf, procédés d'utilisation et d'étalonnage.
EP3434676A4 (fr) Inhibiteur de cdk pyrrolopyrimidine substituée, composition pharmaceutique le comprenant et son utilisation
EP3781563A4 (fr) Inhibiteurs d'hpk1, procédé de préparation et utilisation associés
NO20064194L (no) Fremgangsmate for a modulere IL-23-aktivitet, beslektede reagenser
WO2017156495A8 (fr) Composés et procédés pour moduler la tyrosine kinase de bruton
EP3748995A4 (fr) Procédé de transfert, procédé d'échange d'informations, dispositif, et support de stockage lisible par ordinateur
WO2016172726A9 (fr) Modulateurs de la liaison ror1-ror2
EP3807348A4 (fr) Gels cellulosiques, films et composites comprenant les gels, et procédés de formation de ceux-ci
PH12017502067A1 (en) Insecticidal arylpyrrolidines, method for synthesizing same, and use thereof as agents for controlling animal pests
DK3752490T3 (da) Herbicide 3-azaspiro[5.5]undecan-8,10-dionforbindelser
IL282006B1 (en) Treatment of bone tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
MA46059A (fr) Variants de l'endonucléase homing tim3, compositions et procédés d'utilisation
IL282254A (en) Compounds, compositions, and methods for modulating cdk9 activity
MX2017013248A (es) Compuesto del inhibidor fgfr4 cristalino y usos del mismo.
EP3911207A4 (fr) Ensembles récipients à usage unique pour préparation d'aliments, systèmes et procédés
DK3833434T3 (da) Forbindelser, der er nyttige ved modulering af farnesoid-x-receptoren, samt fremgangsmåder til fremstilling og anvendelse heraf
IL292266A (en) Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benz yl)amino)isoindoline-1,3-dione
EP3868073A4 (fr) Systèmes, procédés et supports de gestion de justificatifs d'utilisateurs
EP3814764A4 (fr) Seringue d'électroséparation et procédés analytiques utilisant la seringue d'électroséparation
PH12020551465A1 (en) Solid forms of substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
EP3434674A4 (fr) Composé ayant une activité inhibitrice de l'idh mutée, son procédé de préparation et son utilisation
IL275153A (en) Fumarate salts of (R)-3-(1-(2, 3-dichloro-4-(pyrazin-2-yl)phenyl)-2,2,2-trifluoroethyl)-1-methyl-1-(1-methylpiperidine) -4-il) Urea, methods for their preparation and use